Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281
6/9/2009 9:21:34 AM
More...
|
Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes Phase II Study in Patients with Impaired Glucose Tolerance Designed to Confirm Therapeutic Activity
2/10/2009 10:32:27 AM
More...
|
Arete Therapeutics Reports Positive Phase I Data for AR9281
12/22/2008 9:55:24 AM
More...
|
Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
11/19/2008 6:14:07 AM
More...
|
Arete Therapeutics Bolsters Management Team Appoints Euan MacIntyre, Ph.D. as Senior Vice President of Drug Discovery
10/30/2008 8:26:14 AM
More...
|
Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
7/8/2008 8:34:44 AM
More...
|
Arete Therapeutics Adds Jim Bristol as Scientific and Strategic Advisor
1/22/2008 8:07:25 AM
More...
|
Arete Therapeutics Appoints Donald Santel to Board of Directors
12/6/2007 11:42:01 AM
More...
|
Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
11/1/2007 7:22:35 AM
More...
|
Arete Therapeutics (Jobs) Raises $35 Million Series A
5/23/2007 10:17:05 AM
More...
|
|